Eurofins Scientific SE ERF.PA
Composite 51/100; the shares have moved about 28% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 35/100 — a moderate mark against it.
Momentum ranks 68/100 — a moderate point in its favour. Valuation ranks 55/100 — a slight point in its favour. Balance-sheet strength ranks 51/100 — a slight point in its favour.
Growth ranks 35/100 — a moderate mark against it. Quality ranks 48/100 — a slight mark against it.
What the company does Eurofins Scientific SE is a global leader in analytical testing and laboratory services, operating across agroscience, biopharma, clinical diagnostics, consumer products, environment, and food/feed testing.
Key financials The company reports ROE 11.3%, ROA 6.0%, and ROCE 17.2%, with gross, operating, and net margins of 23.1%, 16.2%, and 7.2%, respectively. Revenue growth is 2.5% while EPS growth is 28.4%, supported by a Piotroski F-Score of 6/9 and Altman Z of 3.14.
Stock health Sideravia scores the stock at 55.3 overall, with Quality 55.4, Growth 56.9, Strength 55.1, Valuation 51.6, Momentum 58.5, and Income 55.8. The 12-month momentum is 5.36%, with RSI(14) at 53.40.
Price vs fair value The stock trades at a PREMIUM of 49.50% versus our fair-value estimate of 34.66 and at a discount of 5.77% versus the analyst 12-month target of 72.60. - Forward P/E of 16.47 (below trailing 23.79) suggests earnings recovery potential (Valuation data). - PEG of 0.37 indicates undervaluation relative to growth (Valuation data). - Net margins at 7.2% lag gross/operating margins, signaling cost pressures (Key financials). - Debt/Equity at 0.96 and net debt/EBITDA at 2.51 reflect moderate leverage (Key financials). - Dividend yield of 1.1% with a 25.0% payout ratio signals limited income appeal (Key financials).
Looking forward Analysts expect a forward P/E of 16.47 and PEG of 0.37, implying potential upside if growth accelerates. Momentum remains positive at 5.36% over 12 months, though the stock is 6.55% below its 52-week high.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.